LBPO.BCS01 · 生物信息与计算 · Late-Breaking

Twistcgp流程:一个用于转化肿瘤学中全面基因组分析的可移植开源工作流程

Twistcgp pipeline: A portable, open-source workflow for comprehensive genomic profiling in translational oncology

编号 LB162 展板 4 时间 4/20 09:00–12:00 区域 Section 54 主讲 Nils Homer
分会场 Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Nils Homer1, Erin McAuley1, Zach Norgaard1, James Flynn2, Rebecca Barnard2, Tina Han2

1Fulcrum Genomics, Somerville, MA,2Twist Biosciences, South San Francisco, CA

摘要 Abstract

中文摘要
全面基因组分析(CGP)panel被广泛用于转化研究和临床试验,以支持患者分层、探索性生物标志物分析和回顾性分子特征刻画。然而,二次分析和报告工作流程往往作为商业检测生态系统中紧密耦合的专有组件交付。这种耦合限制了透明度、跨中心的可重复性,以及随研究设计和测序技术演进而调整分析方法的灵活性。 我们提出twistcgp,这是一个用于分析Twist Oncology DNA CGP Panel所生成数据的开源生物信息学工作流程,该panel在2.4 Mb范围内靶向562个癌症相关基因,并具备内容定制能力。此项合作将一个聚焦的杂交捕获CGP检测与一个透明、可配置、可移植的分析框架相结合,该框架独立于许可软件、专有执行环境或固定报告层运行。 twistcgp工作流程以Nextflow实现,遵循可重复工作流程设计的社区最佳实践,可在本地基础设施、高性能计算集群或云平台上标准化执行。从FASTQ输入开始,该流程支持比对、体细胞SNV与indel检测、拷贝数变异分析、遵循Friends of Cancer Research协调指南的肿瘤突变负荷(TMB)估算、使用MSIsensor2的微卫星不稳定性(MSI)分类、通过Ensembl VEP和CIViC知识库进行变异注释,以及全面的质量控制报告。 流程性能通过Horizon Discovery、Seracare和Twist参考标准品(使用Twist CGP Panel测序,包括技术重复)进行评估。在所有样本中,该工作流程生成了预期类别的体细胞变异,其标准化质量指标适用于跨样本和跨中心比较。参考物质中的已知变异在预期的VAF下被检出,TMB和MSI估算值与预期一致,且直接从panel数据得出,无需依赖专有分析软件。此外,还在Seqera Platform上评估了执行性能,以支持可扩展部署。 通过将CGP检测化学过程与分析解耦,twistcgp实现了跨分布式研究环境的可重复基因组分析。Twist Oncology DNA CGP Panel与twistcgp工作流程共同展示了一种实用的CGP方法,可减少分析摩擦、支持方法学一致性,并能灵活整合到转化肿瘤学研究中。融合检测计划在未来版本中实现。该流程在GitHub上以MIT许可证免费提供,仅供研究使用。
查看英文原文 English abstract
Comprehensive genomic profiling (CGP) panels are widely used in translational studies & clinical trials to support patient stratification, exploratory biomarker analysis, & retrospective molecular characterization. However, secondary analysis & reporting workflows are often delivered as tightly coupled, proprietary components of commercial assay ecosystems. This coupling limits transparency, reproducibility across sites, & the flexibility to adapt analytical methods as study designs & sequencing technologies evolve. We present twistcgp, an open-source bioinformatics workflow for analysis of data generated with the Twist Oncology DNA CGP Panel that targets 562 cancer-associated genes across 2.4 Mb with the ability to customize content This collaboration pairs a focused hybrid-capture CGP assay with a transparent, configurable, & portable analysis framework that operates independently of licensed software, proprietary execution environments, or fixed reporting layers. The twistcgp workflow is implemented in Nextflow & follows community best practices for reproducible workflow design, enabling standardized execution across local infrastructure, high-performance computing clusters, or cloud platforms. Starting from FASTQ input, the pipeline supports alignment, somatic SNV & indel detection, copy number variant analysis, tumor mutational burden (TMB) estimation following Friends of Cancer Research harmonization guidelines, microsatellite instability (MSI) classification using MSIsensor2, variant annotation via Ensembl VEP & the CIViC knowledgebase, & comprehensive quality control reporting. Pipeline performance was evaluated using Horizon Discovery, Seracare, and Twist reference standards sequenced with the Twist CGP Panel, including technical replicates. Across all samples, the workflow generated expected classes of somatic variation with standardized quality metrics suitable for cross-sample & cross-site comparison. Known variants in reference materials were detected at anticipated VAFs, & TMB & MSI estimates were consistent with expectations, derived directly from panel data with out reliance on proprietary analysis software. Execution performance was also assessed on the Seqera Platform to support scalable deployment. By decoupling CGP assay chemistry from analysis, twistcgp enables reproducible genomic analysis across distributed research environments. Together, the Twist Oncology DNA CGP Panel & twistcgp workflow demonstrate a practical approach to CGP that reduces analytical friction, supports methodological consistency, & enables flexible integration into translational oncology studies. Fusion detection is planned for a future release. The pipeline is freely available on GitHub under MIT license for research use only.
利益披露 Disclosure
N. Homer, None.. E. McAuley, None.. Z. Norgaard, None.. J. Flynn, None.. R. Barnard, None.. T. Han, None.

← 返回 AACR 2026 检索